CI

At a glance

ClinicalIndex Comparison Record
Phase 2Terminated· 37 enrolled
Drug / intervention
Niacin First +4 moredrug
Likely dose
Dose-Establishing Study 1 Niacin 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01237041
NCT01237041Phase 2Terminated
Terminated

Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·interventional·Posted Nov 9, 2010·Updated Dec 17, 2018

In Brief

A Phase 2 clinical trial evaluating Niacin First, Placebo First, and 3 other interventions for Obesity and 2 related conditions. Terminated early, enrolled 37 participants across 1 site.

Signals

Trial was terminated early

Detailed Summary

Background: \- Overweight and obese children and adults often have lower levels of growth hormone in the blood. Regulation of growth hormone may be tied to weight and free fatty acids in the blood. Current tests of growth hormone (such as those used when evaluating the heights of children who are markedly shorter than other children of comparable age) may be affected by other factors, including obesity. Researchers are interested in evaluating the levels of growth hormone and free fatty acids in the blood of children between 7 and 14 years of age who weigh more than children of a comparable age, or who are shorter than other children of a comparable age and have been recommended for growth hormone testing as part of an evaluation for their height. Objectives: \- To determine the effect of changes in free fatty acids in the blood on changes in growth hormone secretion in overweight or shorter children and young adolescents. Eligibility: \- Children and adolescents between 7 and 14 years of age who weigh more than or are shorter than other children of a comparable age and do not have any medical illnesses. Design: * Participants will have two study visits, one of which will be a half day screening visit in the outpatient clinic and one of which will require 2 nights as an inpatient at the National Institutes of Health Clinical Center. * Participants should not eat or drink anything except water after 10 PM the night before or on the morning of the screening visit. * At the screening visit, participants will have a physical examination and medical history, provide blood and urine samples, have an oral glucose tolerance test (to check blood sugar levels), and have an x-ray of the left hand to check bone age. * The inpatient study visit will involve a physical examination and medical history, a full x-ray scan to study body fat and muscle, frequent blood tests throughout the visit, and various medications to stimulate growth hormone production and lower levels of free fatty acids in the blood.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2TerminatedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 9, 2010
Enrollment StartJul 1, 2011
Primary CompletionOct 17, 2017
Study CompletionDec 13, 2017
TodayJul 1, 2026
Enrollment to primary: 6.3 yearsPosted 15.6 years ago

Interventions

Niacin Firstdrug

Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day

Placebo Firstdrug

Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day

Dose-Establishing Study 1 Niacin 250mgdrug

Niacin 250 mg po three times at 2 hour intervals on an inpatient day

Dose-Establishing Study 1 Niacin 500mgdrug

Niacin 500 mg po three times at 2 hour intervals on an inpatient day

Dose-Establishing Study 2 Niacin 500mgdrug

Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day